Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes ( RACELINES ): A randomised, double‐blind trial
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16431 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Michaël J B van Baar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Diabetes Mellitus, Type 2, Gliclazide, Glucosides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Sodium‐glucose cotransporter (SGLT) 2 inhibitors attenuate fasting glomerular hyperfiltration in people with type 2 diabetes (T2D). However, SGLT2‐inhibition increases glucagon levels, which facilitate postprandial hyperfiltration. The impact of SGLT2 inhibition on protein‐related hyperfiltration and postprandial (intra) kidney haemodynamic function is unclear. Moreover, the interaction with dipeptidyl‐peptidase (DPP)‐4 inhibitors, known to reduce glucagon levels and to affect meal‐related factors modulating GFR, is unknown.
Aims
We aimed to assess the effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to the initiation and intensification of SU‐derivative gliclazide treatment on fasting and postprandial kidney haemodynamic function. Materials and Methods We compared three 16‐week glucose‐lowering strategies added to ongoing metformin monotherapy: (1) EMPA‐LINA: 8‐week empagliflozin 10 mg QD (EMPA0‐8w) followed by the addition of 8‐week linagliptin 5 mg QD (LINA8‐16w); (2) LINA‐EMPA: 8‐week linagliptin (LINA0‐8w) followed by the addition of 8‐week empagliflozin (EMPA8‐16w) versus (3) GLIC‐GLIC: 8‐week gliclazide 30 mg QD (GLIC0‐8w) followed by the addition of 8‐week gliclazide 30 mg (GLIC8‐16w). We studied (intra) kidney haemodynamic interactions of this combination using iohexol and PAH clearance techniques to assess measured glomerular filtration rate (mGFR) and effective renal plasma flow (ERPF).
Results
We studied n = 61 overweight people with T2D (HbA1c 62 + 11 mmol/mol, eGFR 89 [78−100] mL/min/1.73 m 2 and urinary albumin‐creatinine‐ratio 1.0 [0.4−1.9] mg/mmol). In the fasting state, EMPA0‐8w (−13.2; −21.3 to −5.1 mL/min) but not LINA0‐8w reduced within‐group mGFR. EMPA8‐16w (−10.2; −16.5 to −4.0 mL/min) but not LINA8‐16w reduced within‐group mGFR. Following a proteinload, EMPA0‐8w (−11.4; −20.2 to −2.6 mL/min) and EMPA8‐16w (−16.2; −22.9 to −9.4 mL/min) but not LINA0‐8w or LINA8‐16w reduced within‐group mGFR. Versus the comparatorarm, fasting mGFR EMPA0‐8w, EMPA8‐16w and EMPA‐LINA and postprandial mGFR EMPA8‐16w and LINA‐EMPA, were significantly reduced. mGFR reductions resulted from intrakidney efferent vasodilation rather than afferent vasoconstriction.
Conclusion
In T2D people without CKD, the favourable kidney haemodynamic effects of empagliflozin persist in the postprandial state and are irrespective of concurrent use of linagliptin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Nephrology and Hypertension, University Medical Center, Utrecht, The Netherlands.
- Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada.
- Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
- Section of Endocrinology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
ORCID-Profile: Michaël J B van Baar, Max Nieuwdorp, David Z I Cherney
Förderung
- Boehringer Ingelheim
Zitieren
APA
van Baar, M. J. B., Muskiet, M. H. A., Scholtes, R. A., Touw, D. J., Nieuwdorp, M., Kramer, M. H. H., Joles, J. A., Cherney, D. Z. I., Bjornstad, P., Krebber, M. M., & van Raalte, D. H. (2025). Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes ( RACELINES ): A randomised, double‐blind trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16431
Vancouver
van Baar MJB, Muskiet MHA, Scholtes RA, Touw DJ, Nieuwdorp M, Kramer MHH, et al. Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes ( RACELINES ): A randomised, double‐blind trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16431
BibTeX
@article{vanBaar2025,
author = {van Baar, Michaël J B and Muskiet, Marcel H A and Scholtes, Rosalie A and Touw, Daan J and Nieuwdorp, Max and Kramer, Mark H H and Joles, Jaap A and Cherney, David Z I and Bjornstad, Petter and Krebber, Merle M and van Raalte, Daniël H},
title = {Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes ( RACELINES ): A randomised, double‐blind trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16431}
}
EUVIMED